EUVIMEDEUVIMED entdecken
Crossref

Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease

Da Young Lee iD, Jun Sung Moon iD, Inha Jung iD, Seung Min Chung iD, So Young Park, Ji Hee Yu, Ji A Seo, Kyung-do Han iD, Nan Hee Kim iD

Diabetes, Obesity and Metabolism · 2025-03 · 27 (3) · 1554-1563

DOI: 10.1111/dom.16165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 02.01.2025. Verfasst von Da Young Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea. Hauptthemen laut MEDLINE: Gout, Renal Insufficiency, Chronic, Cardiovascular Diseases, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Research Foundation of Korea, National IT Industry Promotion Agency (NIPA) grant, Korea Health Industry Development Institute (KHIDI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aimed to examine the impact of gout on cardiovascular disease (CVD) and mortality risk in patients with type 2 diabetes and explore whether chronic kidney disease (CKD) modifies this association. Materials and Methods Using the Korean National Health Insurance Service database, 757 378 individuals with type 2 diabetes were classified into the CKD − Gout − , CKD − Gout + , CKD + Gout − , and CKD + Gout + groups. Cox proportional hazard models were used to assess the risk of myocardial infarction (MI), ischemic stroke, and mortality, after adjusting for cardiometabolic factors.

Results

Over a median follow‐up of 9.3 years, 25 618, 38 691, and 78 628 individuals experienced MI, stroke, and mortality, respectively. The risk of MI or stroke progressively increased across the groups, with the highest adjusted hazard ratio (HR) in the CKD + Gout + group (HR: 1.57, 95% confidence interval [CI]: 1.46–1.69), followed by the CKD + Gout − group (HR: 1.23, 95% CI 1.20–1.26). The CKD + Gout + group showed the greatest risks for MI (HR: 1.71), stroke (HR: 1.46), and mortality (HR: 1.78). Individuals with gout alone did not exhibit a significant increase in risk compared with those without gout or CKD. Interaction analyses indicated that the effect of gout on the outcomes was more pronounced in patients with CKD. Subgroup analyses yielded consistent findings across diverse demographic and clinical characteristics.

Conclusions

CKD with or without gout increased the risk of CVD and mortality, with the highest risk observed in the CKD + Gout + group. The interaction between CKD and gout significantly influenced these outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutRenal Insufficiency, ChronicCardiovascular DiseasesDiabetes Mellitus, Type 2HumansMaleFemaleMiddle AgedRepublic of KoreaAgedRisk FactorsCause of DeathProportional Hazards ModelsMyocardial InfarctionAdultFollow-Up Studies

Stichwörter der Autor:innen

cardiovascular diseasecohort studydatabase researchdiabetes complicationsobservational studytype 2 diabetes

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.
  • Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.

ORCID-Profile: Da Young Lee, Jun Sung Moon, Inha Jung, Seung Min Chung, Kyung-do Han, Nan Hee Kim

Förderung

  • National Research Foundation of Korea
  • National IT Industry Promotion Agency (NIPA) grant
  • Korea Health Industry Development Institute (KHIDI)
  • National IT Industry Promotion Agency

Zitieren

APA

Lee, D. Y., Moon, J. S., Jung, I., Chung, S. M., Park, S. Y., Yu, J. H., Seo, J. A., Han, K. D., & Kim, N. H. (2025). Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 27(3), 1554-1563. https://doi.org/10.1111/dom.16165

Vancouver

Lee DY, Moon JS, Jung I, Chung SM, Park SY, Yu JH, et al. Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism. 2025;27(3):1554-1563. doi:10.1111/dom.16165

BibTeX
@article{Lee2025,
  author = {Lee, Da Young and Moon, Jun Sung and Jung, Inha and Chung, Seung Min and Park, So Young and Yu, Ji Hee and Seo, Ji A and Han, Kyung-do and Kim, Nan Hee},
  title = {Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {1554--1563},
  doi = {10.1111/dom.16165}
}
Kostenlos starten →